BLFS BioLife Solutions, Inc. - Common Stock

NAS · US · Healthcare · Medical Instruments & Supplies · biolifesolutions.com

37.22USD-0.23%Mkt Cap: 1.82B $P/E: 37.30Today

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The…

Industry Peers

Medical Instruments & Supplies

Screen all

ISRG

Intuitive Surgical, Inc. - Common Stock

$140.43BUSDP/E 44.8

EssilorLuxottica Société anonyme

$72.05BUSDP/E 27.0

BDX

Becton, Dickinson and Company Common Stock

$48.16BUSDP/E 30.5

MDLN

Medline Inc. - Class A common stock

$47.91BUSDP/E 44.5

RMD

ResMed Inc. Common Stock

Alcon Inc. Ordinary Shares

$30.82BUSDP/E 48.7

WST

West Pharmaceutical Services, Inc. Common Stock

$25.69BUSDP/E 46.8

DIM

Sartorius Stedim Biotech S.A.

$22.21BUSDP/E 69.8

SRT3

Sartorius Aktiengesellschaft

Sartorius Aktiengesellschaft

$15.16BUSDP/E 71.4

SOLV

Solventum Corporation Common Stock

$14.95BUSDP/E 10.7

BAX

Baxter International Inc. Common Stock

$12.14BUSD

COO

The Cooper Companies, Inc. - Common Stock

$10.82BUSDP/E 19.6

AVTR

Avantor, Inc. Common Stock

$10.38BUSD

COO

The Cooper Companies, Inc.

$10.29BUSDP/E 18.6

RGEN

Repligen Corporation - Common Stock

$10.25BUSDP/E 248.9

ALGN

Align Technology, Inc. - Common Stock

$10.21BUSDP/E 25.0

ATR

AptarGroup, Inc. Common Stock

$7.62BUSDP/E 21.6

Key Statistics

Company

Market Cap1.82B USD

Enterprise Value1.76B USD

Revenue (TTM)106.69M USD

Gross Profit62.12M USD

Net Income (TTM)-4.59M USD

Revenue/Share2.21 USD

Last Price37.22 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees155

CountryUS

SectorHealthcare

IndustryMedical Instruments & Supplies

ISIN—

Valuation

P/E (Trailing)37.30

P/E (Forward)113.03

PEG15.09

EV/EBITDA254.72

EV/Revenue16.47

P/S17.10

P/B4.34

EPS (TTM)0.99

EPS (Forward)0.33

52W Range

17.8688% of range39.76

52W High39.76 USD

52W Low17.86 USD

Profitability

Gross Margin64.56%

Oper. Margin5.96%

EBITDA Margin6.47%

Profit Margin-4.78%

ROE-1.24%

ROA-1.13%

Growth

Revenue Growth21.50%

Earnings Growth—

Cash Flow & Leverage

Operating CF20.11M USD

CapEx (TTM)19.70M USD

FCF Margin4.37%

FCF Yield0.26%

Net Debt-66.68M USD

Net Debt/EBITDA-9.66

Balance Sheet

Debt/Equity0.05

Current Ratio9.69

Quick Ratio6.67

Book Value/Sh8.59 USD

Cash/Share1.69 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split1:14

Split DateJan 29, 2014

Analyst Consensus

Rating—

Target (Mean)31.29 USD

Upside (mean)-15.9%

Target Range31.00 USD – 33.00 USD

31.00-15.9% to mean33.00

# Analysts7

Ownership

Shares Out.48.92M

Float40.12M

Insiders2.61%

Institutions105.48%

Short Interest

Short Ratio4.5d

Short % Float10.82%

Short % Out.7.94%

Shares Short3.88M

Short (prev mo.)4.02M

Technical

SMA 5035.52 (+4.8%)

SMA 20026.55 (+40.2%)

Beta1.92

S&P 52W Chg14.58%

Avg Vol (30d)859.09K

Avg Vol (10d)1.10M

Technical Indicators

RSI (14)55.6

MACD1.0423

MACD Signal1.1719

MACD Hist.-0.1296

BB Upper39.87 USD

BB Middle36.84 USD

BB Lower33.80 USD

BB Width16.48%

ATR (14)1.089 USD

Vol Ratio (20d)3.30x